Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

NCT06326008 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, in Relapse

Interventions

DRUG: Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy

Sponsor

Beijing GoBroad Hospital